Actually, they stop awarding RPDD PRVs next year. Companies which are awarded the designation before that have an additional 2 years to get FDA registration to be awarded the PRV.
Still, that's impossible for AGN. Even if they managed to get the nod for a phase1a/1b followed by a registrational phase 2, it will be at least the end of the decade before the drug is approved in HIE.
Might still be worth applying in the off-chance that the RPDD PRV program keeps getting extended. But unlikely.
.![]()
- Forums
- ASX - By Stock
- AGN
- Ann: Preclinical HIE Study - ARG007 Effective Stand-Alone Therapy
Ann: Preclinical HIE Study - ARG007 Effective Stand-Alone Therapy, page-14
Add AGN (ASX) to my watchlist
|
|||||
Last
79.0¢ |
Change
0.010(1.28%) |
Mkt cap ! $100.4M |
Open | High | Low | Value | Volume |
78.0¢ | 80.5¢ | 78.0¢ | $71.40K | 90.43K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 78.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
80.5¢ | 2444 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 0.785 |
1 | 10000 | 0.780 |
2 | 25477 | 0.775 |
2 | 16000 | 0.770 |
2 | 58000 | 0.760 |
Price($) | Vol. | No. |
---|---|---|
0.805 | 2444 | 1 |
0.830 | 2298 | 2 |
0.850 | 10650 | 2 |
0.860 | 12500 | 1 |
0.865 | 14194 | 2 |
Last trade - 15.55pm 23/08/2024 (20 minute delay) ? |
AGN (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online